BRIEF-Citius Pharmaceuticals Announces FDA Acceptance Of The BLA Resubmission Of LYMPHIR™

Reuters03-18

March 18 (Reuters) - Citius Pharmaceuticals Inc

* CITIUS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF THE BLA RESUBMISSION OF LYMPHIR™ (DENILEUKIN DIFTITOX) FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY CUTANEOUS T-CELL LYMPHOMA

* CITIUS PHARMACEUTICALS INC -FDA ASSIGNS PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF AUGUST 13, 2024

Source text for Eikon: Further company coverage:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2420479170?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-03-18 21:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2420479170","market":"us","top_or_hot":-1,"title":"BRIEF-Citius Pharmaceuticals Announces FDA Acceptance Of The BLA Resubmission Of LYMPHIR™","media":"Reuters","content":"<html><body><p>March 18 (Reuters) - Citius Pharmaceuticals Inc</p><p> :</p><p>   * CITIUS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF THE BLA RESUBMISSION OF LYMPHIR™ (DENILEUKIN DIFTITOX) FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY CUTANEOUS T-CELL LYMPHOMA</p><p>   * CITIUS PHARMACEUTICALS INC -FDA ASSIGNS PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF AUGUST 13, 2024</p><p>Source text for Eikon:    Further company coverage:   </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Citius Pharmaceuticals Announces FDA Acceptance Of The BLA Resubmission Of LYMPHIR™</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Citius Pharmaceuticals Announces FDA Acceptance Of The BLA Resubmission Of LYMPHIR™\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-18 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>March 18 (Reuters) - Citius Pharmaceuticals Inc :   * CITIUS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF THE BLA RESUBMISSION OF LYMPHIR™ (DENILEUKIN DIFTITOX) FOR THE TREATMENT OF ADULTS WITH ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTXR","symbol_name":"Citius Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2420479170","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2420479170","pubTimestamp":1710767702,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"March 18  - Citius Pharmaceuticals Inc :   * CITIUS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF THE BLA RESUBMISSION OF LYMPHIR  FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY CUTANEOUS T-CELL LYMPHOMA   * CITIUS PHARMACEUTICALS INC -FDA ASSIGNS PRESCRIPTION DRUG USER FEE ACT  TARGET ACTION DATE OF AUGUST 13, 2024Source text for Eikon:    Further company coverage:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTXR":"Citius Pharmaceuticals, Inc.","BK4007":"制药"},"translate_title":"简报——花旗制药宣布FDA接受LYMPHIR™公司的BLA重新提交","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTXR":0.9},"content_text":"March 18 (Reuters) - Citius Pharmaceuticals Inc :   * CITIUS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF THE BLA RESUBMISSION OF LYMPHIR™ (DENILEUKIN DIFTITOX) FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY CUTANEOUS T-CELL LYMPHOMA   * CITIUS PHARMACEUTICALS INC -FDA ASSIGNS PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF AUGUST 13, 2024Source text for Eikon:    Further company coverage:","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2420479170"}